The explosion of telehealth ED platforms has been excellent for access — millions of men now get treatment who previously suffered in silence rather than visit a doctor's office. But access without adequate medical oversight carries risks. Several studies, including research from Yale-affiliated investigators, have evaluated the quality of telehealth ED prescribing. The findings are a mixed bag.
What Research Has Found
Studies evaluating direct-to-consumer telehealth ED platforms have identified both strengths and concerning patterns:
Strengths:
- Dramatically improved access — men who would never visit an in-person provider now get treatment
- Reduced stigma — the privacy of telehealth removes a major barrier
- Competitive pricing — market competition has driven generic ED medication costs down
- Convenience — prescriptions are filled and shipped without pharmacy visits
Concerns:
- Insufficient cardiovascular screening. Some platforms prescribe PDE5 inhibitors without adequately assessing cardiovascular risk — missing the opportunity to identify men for whom ED is an early warning sign of heart disease.
- Limited medication interaction review. Asynchronous questionnaire-based prescribing may not catch all contraindicated medication combinations, particularly nitrates.
- Minimal follow-up. Some platforms provide the prescription without structured follow-up to assess effectiveness, side effects, or the need for dose adjustment.
- Inadequate workup for young men. Younger men with ED may need hormonal, psychological, or urological evaluation that a quick telehealth questionnaire doesn't provide.
- Pressure toward proprietary compounds. Some platforms steer toward more expensive compounded formulations when simple generic PDE5 inhibitors would suffice.
The Screening Minimum
A responsible telehealth ED evaluation should include, at minimum:
- Assessment of cardiovascular risk factors and symptoms
- Complete medication list review with specific screening for nitrates, alpha-blockers, and CYP3A4 inhibitors
- Screening for underlying causes (diabetes, hypertension, hormonal issues, depression)
- Assessment of whether ED is situational vs. consistent (which guides the differential diagnosis)
- Follow-up mechanism to assess treatment response and adjust if needed
How to Evaluate a Platform
Not all telehealth ED providers are equal. Quality indicators to look for:
Licensed prescribers. Your prescription should come from a licensed MD, DO, NP, or PA — not a "wellness coach" or uncredentialed advisor. The prescriber's license should be verifiable through your state's medical board.
Real medical intake. A thorough health questionnaire covering cardiac history, medications, allergies, and medical conditions. If a platform prescribes ED medication based only on your name, address, and credit card — that's not medicine.
Live consultation option. Even if the initial evaluation is asynchronous (questionnaire-based), the platform should offer video or phone consultation for complex cases or when the prescriber has questions.
Pharmacy transparency. You should know which pharmacy fills your prescription. Legitimate platforms use NABP-accredited or state-licensed pharmacies.
Follow-up structure. Responsible platforms check in after the initial prescription — at minimum, asking about effectiveness and side effects before refilling.